‘The SECURE study outcomes demonstrate that isavuconazole is usually energetic against both Aspergillus spp. And emerging molds and could represent a step forward for patients experiencing these life-threatening infections,’ said Bernhardt Zeiher, M.D., executive vice president, global development. Isavuconazole posters and presentations at ECCMID 2014 A phase 3 randomised, double-blind trial evaluating isavuconazole vs. Voriconazole for the principal treatment of invasive fungal disease caused by Aspergillus spp. Maertens, T. Patterson, G. Rahav, D. Kontoyiannis, K. Marr, R. Maher, M. Lee, B. Zeiher, A. Seyedmousavi, J. F. Meis, R. J. M. J. G. Melchers, P. E. Verweij, J. W. Warn, A. Sharp; Poster P0106.. Astellas reports efficacy, protection data of isavuconazole invasive aspergillosis SECURE research at ECCMID Astellas reported today that the efficacy and security data of the isavuconazole invasive aspergillosis research were presented at the European Congress of Clinical Microbiology and Infectious Diseases in Barcelona, Spain.Biopsies were done in six months and a complete season after treatment started. The record was presented at most recent getting together with of the American Culture of Clinical Oncology.
CardioTech receives approval for another graft size for CardioPass clinical trial CardioTech International, Inc., a developer and producer of advanced medical gadgets and materials for the treating a broad selection of disease states, today announced that it has received the required Ministry of Health authorization to include a 4mm graft for the clinical trial of CardioPass , the business’s proprietary man made coronary bypass graft. Until now, the trial was only approved for a 5mm graft. Commenting on today’s announcement, CardioTech President and CEO Michael F.